Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 3/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2735417 | 0.83 | CHEK2 (0.60) | CHEK2SLC2A1GPR119ALOX5APFEN1 | |
| SCHEMBL5104980 | 0.83 | CHEK2 (0.43) | CHEK2BACE1 | |
| Bromide SCHEMBL215056 | 0.83 | CHEK2 (0.59) | CHEK2SLC2A1GPR119ALOX5APFEN1 | |
| SCHEMBL215733 | 0.81 | CHEK2 (0.54) | CHEK2SLC2A1GPR119HDAC1ALOX5AP | |
| SCHEMBL2735420 | 0.80 | CHEK2 (0.59) | CHEK2SLC2A1GPR119HDAC1 | |
| SCHEMBL213773 | 0.80 | GPR119 (0.57) | CHEK2SLC2A1GPR119HDAC1ALOX5AP | |
| SCHEMBL215986 | 0.79 | CHEK2 (0.52) | CHEK2SLC2A1GPR119HDAC1ALOX5AP | |
| SCHEMBL22918743 | 0.79 | CHEK2 (0.52) | CHEK2SLC2A1GPR119HDAC1ALOX5AP | |
| SCHEMBL29615310 | 0.79 | CHEK2 (0.52) | CHEK2SLC2A1GPR119HDAC1ALOX5AP | |
| SCHEMBL26668458 | 0.79 | SLC2A1 (0.59) | CHEK2SLC2A1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (UK) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | HIF1AN, HIF1A, CDK2 | CHEK2 137/4885SLC2A1 2572/4885GPR119 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.